Table 1 Characteristics of participants.

From: Multicenter, prospective clinical trial for balloon-occluded alternative infusion of cisplatin solution and fragmented gelatin particles of transarterial chemoembolization for hepatocellular carcinoma beyond up-to-seven criteria

Characteristic

Values

Age (y)

Mean (Range)

77.6 (66–94)

Sex

Male/Female

14/4

Maximum tumor diameter (mm)

Mean (Range)

39.2 (12–143)

Number of tumors

Mean (Range)

9.4 (3–20)

Performance status

0/1

16/2

Etiology

HCV/HBV/Alc/NASH/Others

7/1/5/3/3

(One patient with a co-infection of HBV and HCV)

Previous therapy

Surgery/RFA/TACE

4/3/9

AFP (ng/ml)

< 10 /10–400/ > 400

8/5/5

PIVKA-II (nAU/ml)

< 40 / ≥ 40

4/14

Child–Pugh score

5/6/ ≥ 7

14/4/0

Up-to-11 Out/Up-to-7 Out

13/18

  1. HCV, hepatitis C virus; HBV, hepatitis B virus; Alc, alcohol; NASH, non-alcoholic steatohepatitis; RFA, radiofrequency ablation; TACE, transarterial chemoembolization; AFP, alpha-fetoprotein; PIVKA, protein induced by vitamin K absence.
Back to article page